Status update regarding the completion of Lumito’s first product
The development of Lumito’s first product (instrument + staining reagent) in digital tissue diagnostics, for analyzing tissue sections stained with the company’s nano-based staining reagents, is entering its final stage prior to launch. The development of the actual instrument is proceeding according to plan, and the first instruments, which are intended for customer validation at […]
Andreas Johansson – the new CTO
Andreas Johansson will take over as CTO on January 13, 2020, taking the place of Anders Sjögren who held this position since spring 2017. Anders remains in Lumito's organisation as a senior adviser and will continue to contribute to the company's development. – I look forward to starting as Lumito’s CTO. This is an innovative, […]
First exercise window for Lumito warrants closes
On 29 November, Lumito AB (publ) (“Lumito”) ended the first exercise period for the Series 2 TO2 subscription warrant. The exercise rate was 72.3 percent, at an exercise price of SEK 1.45 per share. In total, 11,179,281 new shares have been subscribed during the now concluded first exercise period. Lumito is thus provided approximately MSEK […]
Lumito – winner in the poster competition and awarded with a presentation at the Digital Pathology & AI Congress in London
Lumito has been selected by the conference committee as the winner of the poster competition and has been awarded a 15 min presentation at the Digital Pathology & AI Congress in London on 5-6 December. Lumito will be presented to over 420 attendees and 35 exhibitors at the sold out meeting. Krzysztof Krawczyk, R&D Manager […]
Lumito’s main owner, CEO and a member of the board exercise their subscription warrants in full
During the first exercise window, Lumito's major shareholder, Cardeon Futuring Finance (40 percent of which is owned by Masoud Khayyami), Lumito's CEO, Stefan Nilsson, and member of the board Ulf Bladin have exercised all of their Series TO2 warrants to subscribe for shares in Lumito AB. In total, this amounts to 2,130,000 subscription warrants. After the […]
Important progress in product development – simultaneous staining in the same section, with high degree of detail
Lumito is developing a novel method for high-contrast imaging without background signal. The first application is developed for tissue diagnostics and digital pathology. In order to visualize cells containing Her2, which is a common marker in breast cancer diagnostics, Lumito is now presenting new images of breast tissues stained with the Company's Her2-UCNP reagent. Lumito's […]
The alpha prototype of the instrument delivered to Lumito according to plan
Lumito’s development partner TTP has delivered the alpha prototype of what will be Lumito’s first product. After delivery, the instrument has successfully undergone internal acceptance testing. The ongoing development phase of Lumito’s first product includes the development of an alpha prototype, with essential functionality implemented (“work like”), and thereafter a beta prototype, with complete implementation […]
Annual General Meeting of Lumito AB (publ) 2019
The annual general meeting of Lumito AB (publ), held in Lund on 4 June 2019, passed the following resolutions. Resolution on approval of the income statement and balance sheet, etc. The annual general meeting resolved to approve the income statement and balance sheet for the financial year 2018. The Board of Directors and the Managing […]
Lumito holds presentation on the Nordic Symposium on Digital Pathology
On 16 May, Lumito will demonstrate its technology under the theme "Open Innovation" on the Nordic Symposium on Digital Pathology in Linköping, with 200 expected participants from more than 10 countries. – This is an excellent opportunity to give a comprehensive presentation of our technology, and to meet pathologists and other representatives in the field […]
Communiqué from the extraordinary general meeting of Lumito AB (publ)
The extraordinary general meeting of Lumito AB (publ) on 25 April 2019 passed the following resolutions: Item 7 – Decision regarding the approval of the Board of Directors's proposal to issue new shares and warrants (units) Lumito’s Board of Directors has, conditional on the approval of the General Meeting, resolved to conduct a new issue […]
